drugset / Trial / NCT05003648
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
Phase 4
Active not recruiting
24 enrolled
Massachusetts General Hospital
European Leukodystrophy Association · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The investigators recently observed that up to 25% of women with X-linked adrenoleukodystrophy (ALD) have moderate to severe Restless Leg Syndrome (RLS). In this study, the investigators aim to estimate the prevalence of RLS among women with ALD and to assess whether pramipexole improves RLS symptoms as well as sleep and gait measures in women with ALD.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2025-07-16
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pramipexole | Unknown | 0.5 mg | — |